Collaboration
Pro-Cure Therapeutics Limited and Adjuvantix Limited have agreed a research and development collaboration that aims to develop a cancer stem cell vaccine for the treatment and prevention of prostate cancer.
There is strong evidence that cancer stem cells (CSCs) initiate cancers as well as leading to cancer spread and to recurrence after treatments. Pro-Cure, a cancer stem cell specialist, has successfully identified new CSC-derived targets that it believes will provide the foundation for the development of more effective cancer treatments.
The collaboration will bring together Pro-Cure’s proprietary CSC targets and expertise in prostate cancer with Adjuvantix’s expertise in vaccine discovery and development.
Mick McLean, CEO of Pro-Cure, said, “We believe this is the first programme aimed at developing a vaccine against cancer stem cells.”
The two companies are funded by the White Rose Technology Seedcorn Fund which supports new technology emerging from the universities of York, Leeds and Sheffield.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.